IDH2 and acute myeloid leukemia: In line with this observation, CD34+ cells isolated from an IDH2MUT AML patient undergoing treatment with Enasidenib, an IDH2 inhibitor, showed a progressive improvement in their differentiation capacity, as supported by the in vitro generation of colonies of mature hematopoietic cells [19].